Authors

Latest:

Examining the Landscape: PD-1 Inhibitors in R/M NPC

Panelists discuss the efficacy of multiple PD-1 inhibitors studied in nasopharyngeal cancer (NPC), noting similar overall outcomes despite differences in trial designs and adverse effect profiles, challenges in direct comparisons due to crossover and varying chemotherapy backbones, and how limited US approvals impact clinical choice—yet collectively these data affirm the integral role of PD-1 blockade as a cornerstone of treatment.

Barbara Daly, PhD, RN

Latest:

The Benefits for Nurses of Using Psychosocial Cancer Registry Data

Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.

Barbara Given, PhD, RN, FAAN, MSU

Barbara J. Gitlitz

Latest:

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

Barbara J. Gitlitz, MD

Latest:

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Barbara J. Lennert, RN, BSN, MAOM

Latest:

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

Barbara Jones

Latest:

Data Support Safety and Benefit of Chemotherapy Before Radical Cystectomy

Preoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.

Barbara L. Jones

Latest:

B-Cell Malignancies: Transforming Expectations and Outcomes

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.

Barbara Marino, PhD

Latest:

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Barbara McAneny, MD

Latest:

Proving That Value-Based Care Is Possible

More than 2 years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015, the progression toward value-based care has challenged oncologists to assume an unprecedented degree of accountability for the well-being and holistic care of their patients.

Barbara Rapchak

Latest:

Cell Phone-based Telemonitoring Helps Cancer: Patients Adhere to Treatment Regimens

Wireless technologies like cell phones and radio frequency identification can help improve treatment compliance and quality of life for cancer patients.

Barry A. Paul, MD

Latest:

Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Barry Fortner, PhD

Latest:

Community Practice Provides Model for Finding New Revenue in COVID-19 Era

The coronavirus disease 2019 pandemic is highlighting how independent community oncology practices are the best source for patients to receive care close to home, while also presenting several challenges for practices and their patients.

Barry M. Berger, MD

Latest:

Dr. Berger on the Significance of the Cologuard Screening Test

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Barry M. Berger, MD, FACP

Latest:

Dr. Berger on Benefits of New Screening Test for CRC

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses Cologuard screening test for colorectal cancer (CRC).

Barry Rosenbloom, MD

Latest:

Dr. Rosenbloom on Gaucher Disease Diagnosis Challenges

Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges

Bart Frizzell, MD

Latest:

Advancing Prostate Cancer Care

The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.

Bart L. Scott, MD

Latest:

The Future of Chronic GvHD Treatment

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.

Bart Scott, MD

Latest:

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Basem William, MD, MRCP, FACP

Latest:

Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell Lymphoma

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.